Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes

Introduction The PIONEER 7 trial demonstrated superior glycemic control and weight loss with once- daily oral semaglutide with flexible dose adjustment versus sitagliptin 100 mg in type 2 diabetes. This 52- week extension evaluated long- term oral semaglutide treatment body weight reductions, and was well tolerated. Switching from sitagliptin to flexibly dosed oral semaglutide maintained HbA 1c reductions, helped more patients achieve HbA 1c targets with less use of additional glucose- lowering medication, and offers the potential for additional reductions in body weight.